Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program.

Redell M, Moeck G, Lucasti C, Durso S, Kennedy C, Fusaro K, Loutit J, Dudley M.

Open Forum Infect Dis. 2018 Mar 19;5(6):ofy051. doi: 10.1093/ofid/ofy051. eCollection 2018 Jun.

2.

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.

Corey GR, Loutit J, Moeck G, Wikler M, Dudley MN, O'Riordan W; SOLO I and SOLO II investigators.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01919-17. doi: 10.1128/AAC.01919-17. Print 2018 Apr.

3.
4.

Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection.

Belley A, Lalonde-Séguin D, Arhin FF, Moeck G.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01265-17. doi: 10.1128/AAC.01265-17. Print 2017 Oct.

5.

In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.

Arhin FF, Seguin DL, Belley A, Moeck G.

Diagn Microbiol Infect Dis. 2017 Oct;89(2):168-171. doi: 10.1016/j.diagmicrobio.2017.06.023. Epub 2017 Jul 1.

PMID:
28733126
6.

Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci.

Arhin FF, Moeck G.

J Glob Antimicrob Resist. 2017 Jun;9:85-86. doi: 10.1016/j.jgar.2017.03.002. Epub 2017 Apr 25. No abstract available.

PMID:
28455075
7.
8.

In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.

Karlowsky JA, Walkty AJ, Baxter MR, Arhin FF, Moeck G, Adam HJ, Zhanel GG.

Diagn Microbiol Infect Dis. 2017 Apr;87(4):349-356. doi: 10.1016/j.diagmicrobio.2017.01.006. Epub 2017 Jan 20.

PMID:
28159446
9.

Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.

Belley A, Robson R, Francis JL, Adcock DM, Tiefenbacher S, Rubino CM, Moeck G, Sylvester D, Dudley MN, Loutit J.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01968-16. doi: 10.1128/AAC.01968-16. Print 2017 Feb.

10.

Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Sweeney D, Shinabarger DL, Arhin FF, Belley A, Moeck G, Pillar CM.

Diagn Microbiol Infect Dis. 2017 Feb;87(2):121-128. doi: 10.1016/j.diagmicrobio.2016.11.002. Epub 2016 Nov 12.

PMID:
27890418
11.

Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci.

Sweeney D, Stoneburner A, Shinabarger DL, Arhin FF, Belley A, Moeck G, Pillar CM.

J Antimicrob Chemother. 2017 Feb;72(2):622-624. doi: 10.1093/jac/dkw451. Epub 2016 Nov 17. No abstract available.

PMID:
27856721
12.

Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.

Corey GR, Arhin FF, Wikler MA, Sahm DF, Kreiswirth BN, Mediavilla JR, Good S, Fiset C, Jiang H, Moeck G, Kabler H, Green S, O'Riordan W; SOLO I, SOLO II Investigators.

Int J Antimicrob Agents. 2016 Nov;48(5):528-534. doi: 10.1016/j.ijantimicag.2016.07.019. Epub 2016 Sep 13.

PMID:
27665522
13.

Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.

Belley A, Lalonde Seguin D, Arhin F, Moeck G.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4342-5. doi: 10.1128/AAC.00169-16. Print 2016 Jul.

14.

Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.

Jones RN, Moeck G, Arhin FF, Dudley MN, Rhomberg PR, Mendes RE.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3174-7. doi: 10.1128/AAC.03029-15. Print 2016 May.

15.

In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.

Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF.

Int J Antimicrob Agents. 2015 Dec;46(6):674-81. doi: 10.1016/j.ijantimicag.2015.08.014. Epub 2015 Oct 20.

PMID:
26541881
16.

Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.

Rubino CM, Bhavnani SM, Moeck G, Bellibas SE, Ambrose PG.

Antimicrob Agents Chemother. 2015;59(6):3365-72. doi: 10.1128/AAC.00176-15. Epub 2015 Mar 30.

17.

Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.

Jones RN, Turnidge JD, Moeck G, Arhin FF, Mendes RE.

Antimicrob Agents Chemother. 2015 Apr;59(4):2405-9. doi: 10.1128/AAC.05098-14. Epub 2015 Feb 9.

18.

Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.

Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, Manos P, Keech R, Singh R, Heller B, Bubnova N, O'Riordan W; SOLO II Investigators.

Clin Infect Dis. 2015 Jan 15;60(2):254-62. doi: 10.1093/cid/ciu778. Epub 2014 Oct 6.

PMID:
25294250
19.

Dalbavancin or oritavancin for skin infections.

Corey GR, Jiang H, Moeck G.

N Engl J Med. 2014 Sep 18;371(12):1162-3. doi: 10.1056/NEJMc1407925. No abstract available.

PMID:
25243251
20.

In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene.

Arhin FF, Sarmiento I, Moeck G.

Int J Antimicrob Agents. 2014 Jul;44(1):65-8. doi: 10.1016/j.ijantimicag.2014.03.015. Epub 2014 May 23.

PMID:
24906505
21.

Single-dose oritavancin in the treatment of acute bacterial skin infections.

Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, Giordano P, Lucasti C, Perez A, Good S, Jiang H, Moeck G, O'Riordan W; SOLO I Investigators.

N Engl J Med. 2014 Jun 5;370(23):2180-90. doi: 10.1056/NEJMoa1310422.

22.

Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA).

Arhin FF, Sarmiento I, Moeck G.

Int J Antimicrob Agents. 2013 Apr;41(4):397-8. doi: 10.1016/j.ijantimicag.2012.12.004. Epub 2013 Jan 29. No abstract available.

PMID:
23374976
23.

Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.

Belley A, Arhin FF, Sarmiento I, Deng H, Rose W, Moeck G.

Antimicrob Agents Chemother. 2013 Jan;57(1):205-11. doi: 10.1128/AAC.01428-12. Epub 2012 Oct 22.

24.

Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.

Freeman J, Marquis M, Crowther GS, Todhunter SL, Fawley WN, Chilton CH, Moeck G, Lehoux D, Wilcox MH.

J Antimicrob Chemother. 2012 Dec;67(12):2919-26. doi: 10.1093/jac/dks309. Epub 2012 Aug 16.

PMID:
22899803
25.

Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci.

Arhin FF, Draghi DC, Pillar CM, Moeck G, Sahm DF.

Int J Antimicrob Agents. 2012 Dec;40(6):562-3. doi: 10.1016/j.ijantimicag.2012.06.019. Epub 2012 Aug 4. No abstract available.

PMID:
22871370
26.

Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus.

Arhin FF, Sarmiento I, Parr TR Jr, Moeck G.

Int J Antimicrob Agents. 2012 Feb;39(2):159-62. doi: 10.1016/j.ijantimicag.2011.09.017. Epub 2011 Nov 8.

PMID:
22070858
27.

Genome annotation and intraviral interactome for the Streptococcus pneumoniae virulent phage Dp-1.

Sabri M, Häuser R, Ouellette M, Liu J, Dehbi M, Moeck G, García E, Titz B, Uetz P, Moineau S.

J Bacteriol. 2011 Jan;193(2):551-62. doi: 10.1128/JB.01117-10. Epub 2010 Nov 19.

28.

Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.

Belley A, McKay GA, Arhin FF, Sarmiento I, Beaulieu S, Fadhil I, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2010 Dec;54(12):5369-71. doi: 10.1128/AAC.00760-10. Epub 2010 Sep 27.

29.

Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.

Arhin FF, Moeck G, Draghi DC, Pillar CM, Sahm DF.

Int J Antimicrob Agents. 2010 Nov;36(5):474-6. doi: 10.1016/j.ijantimicag.2010.07.010. Epub 2010 Sep 16. No abstract available.

PMID:
20846829
30.

Assessment of oritavancin serum protein binding across species.

Arhin FF, Belley A, McKay G, Beaulieu S, Sarmiento I, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2010 Aug;54(8):3481-3. doi: 10.1128/AAC.00271-10. Epub 2010 May 24.

31.

Characterization of the in vitro activity of novel lipoglycopeptide antibiotics.

Arhin FF, Belley A, McKay GA, Moeck G.

Curr Protoc Microbiol. 2010 Feb;Chapter 17:Unit17.1. doi: 10.1002/9780471729259.mc1701s16.

PMID:
20131224
32.

Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis.

Tanaka KS, Dietrich E, Ciblat S, Métayer C, Arhin FF, Sarmiento I, Moeck G, Parr TR Jr, Far AR.

Bioorg Med Chem Lett. 2010 Feb 15;20(4):1355-9. doi: 10.1016/j.bmcl.2010.01.006. Epub 2010 Jan 11.

PMID:
20097069
33.

Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes.

Arhin FF, McKay GA, Beaulieu S, Sarmiento I, Parr TR Jr, Moeck G.

Int J Antimicrob Agents. 2009 Dec;34(6):550-4. doi: 10.1016/j.ijantimicag.2009.08.012. Epub 2009 Oct 8.

PMID:
19818587
34.

Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus.

Arhin FF, McKay GA, Beaulieu S, Sarmiento I, Parr TR Jr, Moeck G.

Diagn Microbiol Infect Dis. 2009 Oct;65(2):207-10. doi: 10.1016/j.diagmicrobio.2009.05.022.

PMID:
19748436
35.

Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital.

Vaudaux P, Huggler E, Arhin FF, Moeck G, Renzoni A, Lew DP.

Int J Antimicrob Agents. 2009 Dec;34(6):540-3. doi: 10.1016/j.ijantimicag.2009.07.016. Epub 2009 Sep 9.

PMID:
19744838
36.

Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates.

Arhin FF, Kurepina N, Sarmiento I, Parr TR Jr, Moeck G, Kreiswirth B.

Int J Antimicrob Agents. 2010 Jan;35(1):93-4. doi: 10.1016/j.ijantimicag.2009.07.012. Epub 2009 Sep 9. No abstract available.

PMID:
19744836
37.

Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.

Arhin FF, Draghi DC, Pillar CM, Parr TR Jr, Moeck G, Sahm DF.

Antimicrob Agents Chemother. 2009 Nov;53(11):4762-71. doi: 10.1128/AAC.00952-09. Epub 2009 Sep 8.

38.

Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin.

Arhin FF, Sarmiento I, Parr TR Jr, Moeck G.

J Antimicrob Chemother. 2009 Oct;64(4):868-70. doi: 10.1093/jac/dkp286. Epub 2009 Aug 4. No abstract available.

PMID:
19656783
39.

Inhibition of transcription in Staphylococcus aureus by a primary sigma factor-binding polypeptide from phage G1.

Dehbi M, Moeck G, Arhin FF, Bauda P, Bergeron D, Kwan T, Liu J, McCarty J, Dubow M, Pelletier J.

J Bacteriol. 2009 Jun;191(12):3763-71. doi: 10.1128/JB.00241-09. Epub 2009 Apr 17.

40.

Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.

McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T Jr, Moeck G.

J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126. Epub 2009 Apr 15.

PMID:
19369269
41.

Impact of human serum albumin on oritavancin in vitro activity against enterococci.

McKay GA, Beaulieu S, Sarmiento I, Arhin FF, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2009 Jun;53(6):2687-9. doi: 10.1128/AAC.00197-09. Epub 2009 Apr 6.

42.

Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

Belley A, Neesham-Grenon E, McKay G, Arhin FF, Harris R, Beveridge T, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2009 Mar;53(3):918-25. doi: 10.1128/AAC.00766-08. Epub 2008 Dec 22.

43.

Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.

Belley A, Harris R, Beveridge T, Parr T Jr, Moeck G.

Antimicrob Agents Chemother. 2009 Feb;53(2):800-4. doi: 10.1128/AAC.00603-08. Epub 2008 Nov 24.

44.

Bisphosphonated benzoxazinorifamycin prodrugs for the prevention and treatment of osteomyelitis.

Reddy R, Dietrich E, Lafontaine Y, Houghton TJ, Belanger O, Dubois A, Arhin FF, Sarmiento I, Fadhil I, Laquerre K, Ostiguy V, Lehoux D, Moeck G, Parr TR Jr, Rafai Far A.

ChemMedChem. 2008 Dec;3(12):1863-8. doi: 10.1002/cmdc.200800255. No abstract available.

PMID:
18973169
45.

Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis.

Houghton TJ, Tanaka KS, Kang T, Dietrich E, Lafontaine Y, Delorme D, Ferreira SS, Viens F, Arhin FF, Sarmiento I, Lehoux D, Fadhil I, Laquerre K, Liu J, Ostiguy V, Poirier H, Moeck G, Parr TR Jr, Far AR.

J Med Chem. 2008 Nov 13;51(21):6955-69. doi: 10.1021/jm801007z. Epub 2008 Oct 4.

PMID:
18834106
46.

Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis.

Tanaka KS, Houghton TJ, Kang T, Dietrich E, Delorme D, Ferreira SS, Caron L, Viens F, Arhin FF, Sarmiento I, Lehoux D, Fadhil I, Laquerre K, Liu J, Ostiguy V, Poirier H, Moeck G, Parr TR Jr, Rafai Far A.

Bioorg Med Chem. 2008 Oct 15;16(20):9217-29. doi: 10.1016/j.bmc.2008.09.010. Epub 2008 Sep 9.

PMID:
18815051
47.

Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.

Belley A, Neesham-Grenon E, Arhin FF, McKay GA, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2008 Oct;52(10):3820-2. doi: 10.1128/AAC.00361-08. Epub 2008 Jul 21.

48.

Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters.

Arhin FF, Tomfohrde K, Draghi DC, Aranza M, Parr TR Jr, Sahm DF, Moeck G.

Diagn Microbiol Infect Dis. 2008 Sep;62(1):92-5. doi: 10.1016/j.diagmicrobio.2008.05.009. Epub 2008 Jul 9.

PMID:
18614315
49.

Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.

Heine HS, Bassett J, Miller L, Bassett A, Ivins BE, Lehoux D, Arhin FF, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2008 Sep;52(9):3350-7. doi: 10.1128/AAC.00360-08. Epub 2008 Jul 7.

50.

Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Arhin FF, Sarmiento I, Belley A, McKay GA, Draghi DC, Grover P, Sahm DF, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2008 May;52(5):1597-603. doi: 10.1128/AAC.01513-07. Epub 2008 Feb 25.

Supplemental Content

Support Center